Paper Details

  1. Home
  2. Paper Details

Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial.

Author: LehtinenK, Leirisalo-RepoM, LuukkainenR, MutruO, NissiläM, Yli-KerttulaU

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the effectiveness of sulfasalazine in treating 85 patients with active ankylosing spondylitis (AS). Patients were randomly assigned to receive either sulfasalazine or placebo for 26 weeks. Sulfasalazine significantly improved various symptoms, including morning stiffness and chest expansion, compared to baseline. It also reduced inflammation markers and immunoglobulin levels in the blood. At the end of the study, significant differences were seen between the sulfasalazine and placebo groups. Only two patients in each group stopped treatment due to side effects. The study concludes that sulfasalazine is an effective and well-tolerated treatment for active AS.
Paper Details　
Original Abstract of the Article :
Eighty-five patients with active ankylosing spondylitis (AS) were randomized to receive either sulfasalazine (less than or equal to 3 gm/day, mean 2.5) or placebo for 26 weeks. There was a statistically significant improvement, compared with baseline, in most of the clinical variables in patients re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/art.1780310905

データ提供：米国国立医学図書館（NLM）

Sulfasalazine: A Potential Oasis for Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting the spine and other joints. This research investigates the effectiveness of sulfasalazine in treating active AS. The study compared the effects of sulfasalazine with placebo in patients with AS, seeking to evaluate the potential benefits of this medication. This is like exploring different paths in the desert of AS, searching for an effective and safe route to relief.

Sulfasalazine: A Ray of Hope in the Desert of AS

The study found that sulfasalazine showed significant improvement in various clinical variables, suggesting a beneficial effect on active AS. This is like discovering a spring of water in the desert of AS, offering a potential source of relief and a pathway to better health. The study also found that sulfasalazine was well-tolerated, suggesting a safe and effective treatment option for patients with AS.

Navigating the Challenges of AS Treatment

The research emphasizes the need for effective and well-tolerated treatment options for AS. This is like finding a reliable camel to carry you through the desert of AS, ensuring a comfortable and manageable journey. The findings highlight the importance of continuing to explore new and effective therapies for this chronic inflammatory disease.

Dr. Camel's Conclusion

This study provides evidence for the effectiveness of sulfasalazine in treating active AS. The findings suggest that sulfasalazine could offer a valuable treatment option for patients with AS, providing relief from pain and inflammation. This research is like finding a hidden oasis in the desert of AS, offering a haven of relief and a pathway to better health.

Date :
  1. Date Completed 1988-10-19
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

2901839

DOI: Digital Object Identifier

10.1002/art.1780310905

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.